Nuo Therapeutics and PAM Health Partner to Advance Access to Regenerative Wound Healing Therapies
Rhea-AI Summary
Nuo Therapeutics (OTCQB: AURX) has entered a multi-year exclusive agreement with PAM Health to provide its Aurix System as the sole platelet-rich plasma (PRP) wound care therapy across PAM Health's network. The partnership spans all PAM Health's facilities including long-term acute care hospitals, rehabilitation centers, and wound care clinics across 23 states.
The Aurix System, the first FDA-cleared autologous PRP therapy for chronic wounds, utilizes a one-minute spin process to create a biologically active gel from the patient's platelets and plasma. Clinical studies, including collaborations with Medicare & Medicaid Services, have shown superior healing rates compared to other advanced wound modalities.
This partnership addresses a significant healthcare challenge, as chronic wounds affect 2% of the US population and over 8 million Medicare beneficiaries, with annual Medicare spending ranging from $28.1 to $96.8 billion. The condition leads to over 100,000 diabetic amputations annually, with a five-year post-amputation mortality rate of nearly 62%.
Positive
- Secured exclusive multi-year agreement with PAM Health network of over 100 hospitals and clinics
- Expanding market reach across 23 states through PAM Health's network
- Clinical studies demonstrate superior healing rates compared to other advanced wound modalities
- Targeting large market opportunity with 8 million+ Medicare beneficiaries affected by chronic wounds
Negative
- Operating in highly competitive wound care market with $28.1-96.8B Medicare spending
News Market Reaction – AURX
In the trading session that priced this news, AURX gained 9.09%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an innovative new treatment to accelerate chronic wound healing. A multi-year exclusive agreement between PAM Health and Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company at the forefront of biodynamic therapies, means Nuo’s Aurix System will serve as the sole platelet-rich plasma (PRP) wound care therapy across all of PAM Health’s long-term acute care hospitals, inpatient rehabilitation hospitals, and outpatient and wound care clinics. This collaboration will make advanced regenerative treatment more widely available for patients suffering from chronic non-healing wounds.
Representing a silent epidemic in the United States, chronic wounds annually affect an estimated
“The collaboration with PAM Health is about more than product distribution, it’s about aligning missions,” said Dave Hazard, Nuo’s Vice President, Sales. “PAM Health is a trusted leader in patient care. Their clinical reach across 23 states positions them to significantly expand access to the Aurix System. Together, we aim to reduce complications, improve healing times, and most importantly, elevate patient outcomes.”
The Aurix System is the first FDA-cleared autologous PRP therapy specifically indicated for the management of chronic wounds. With a streamlined, one-minute spin process, Aurix produces a biologically active gel using a patient's own platelets and plasma, supporting healing through the natural regenerative cycle. Clinical studies, including those in collaboration with the Centers for Medicare & Medicaid Services, have demonstrated Aurix’s success in accelerating healing compared to other advanced wound modalities.
“At PAM Health, we are committed to delivering clinical excellence to our patients through evidence-based, outcome-driven therapies,” said Nick Fazzolari, SVP, Chief Business Officer, PAM Health. “Adding the Aurix System to our advanced wound care services reflects our unwavering dedication to innovative, patient-centered solutions that optimize healing, reduce complications, and support long-term well-being. This collaboration is a natural extension of our mission to deliver transformative care solutions and reflects the values guiding our pursuit of excellence across the post-acute continuum.”
With over 100 hospitals and specialty clinics, PAM Health continues to lead by example, integrating data-driven innovation and compassionate care. The integration of Aurix PRP into its wound care services reflects PAM Health’s broader strategic vision to provide comprehensive, cost-effective care solutions for patients with complex, chronic conditions, particularly those at risk of limb loss and hospital readmission.
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a commercial-stage medical device company pioneering biodynamic therapies that harness the body’s innate healing abilities. The company’s flagship product, the Aurix System, is an FDA-cleared autologous PRP therapy indicated for the management of chronic wounds. Learn more at www.nuot.com.
About PAM Health
PAM Health, based in Enola, Pennsylvania, provides post-acute healthcare services through more than 100 long-term acute care hospitals, medical rehabilitation hospitals, behavioral health hospitals, as well as wound care clinics and outpatient physical therapy locations, in 23 states. PAM Health is committed to providing high-quality patient care and outstanding customer service, coupled with loyal, dedicated, and highly trained staff, to be the most trusted and impactful source for healthcare services in every community it serves. Learn more at PAMHealth.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo's management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in the Nuo's public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo's annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.
References
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017). Diabetic foot ulcers and their recurrence. The New England Journal of Medicine, 376(24), 2367-2375.
https://doi.org/10.1056/NEJMra1615439
Nussbaum, S. R., Carter, M. J., Fife, C. E., DaVanzo, J. E., Haught, R., Nusgart, M., & Cartwright, D. (2018). An economic evaluation of the impact, cost, and Medicare policy implications of chronic nonhealing wounds. Value in Health, 21(1), 27–32.
https://doi.org/10.1016/j.jval.2017.07.007
Rice, J. B., Desai, U., Cummings, A. K. G., Birnbaum, H. G., Skornicki, M., & Parsons, N. (2014). Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care, 37(3), 651–658.
https://doi.org/10.2337/dc13-2176
David Jorden
djorden@nuot.com
